205 related articles for article (PubMed ID: 37467664)
1. A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism.
Yao Y; Zhang Y; Li Z; Chen Z; Wang X; Li Z; Yu L; Cheng X; Li W; Jiang WJ; Wu HJ; Feng Z; Sun J; Fei T
Biochem Biophys Res Commun; 2023 Oct; 675():113-121. PubMed ID: 37467664
[TBL] [Abstract][Full Text] [Related]
2. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
[TBL] [Abstract][Full Text] [Related]
3. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.
Chan SW; Shafi T; Ford RC
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835112
[TBL] [Abstract][Full Text] [Related]
4. In Silico Screening and Testing of FDA-Approved Small Molecules to Block SARS-CoV-2 Entry to the Host Cell by Inhibiting Spike Protein Cleavage.
Ozdemir ES; Le HH; Yildirim A; Ranganathan SV
Viruses; 2022 May; 14(6):. PubMed ID: 35746605
[TBL] [Abstract][Full Text] [Related]
5. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
6. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
8. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
9. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
10. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
11. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2.
Chandel V; Sharma PP; Raj S; Choudhari R; Rathi B; Kumar D
J Biomol Struct Dyn; 2022 Jan; 40(1):249-262. PubMed ID: 32838660
[TBL] [Abstract][Full Text] [Related]
12. Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2.
Mujwar S
Comput Biol Med; 2021 Sep; 136():104748. PubMed ID: 34388463
[TBL] [Abstract][Full Text] [Related]
13. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
14. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.
Feng Z; Chen M; Xue Y; Liang T; Chen H; Zhou Y; Nolin TD; Smith RB; Xie XQ
Brief Bioinform; 2021 Mar; 22(2):946-962. PubMed ID: 33078827
[TBL] [Abstract][Full Text] [Related]
15. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
17. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
18.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
19. A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2.
Su X; Hu L; You Z; Hu P; Wang L; Zhao B
Brief Bioinform; 2022 Jan; 23(1):. PubMed ID: 34965582
[TBL] [Abstract][Full Text] [Related]
20. In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J).
Kalamatianos KG
Mol Divers; 2023 Jun; 27(3):1087-1099. PubMed ID: 35739375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]